Viridian Therapeutics Completes Enrollment Of THRIVE-2 For VRDN-001 In Patients With Chronic Thyroid Eye Disease
Portfolio Pulse from Benzinga Newsdesk
Viridian Therapeutics has completed enrollment for its THRIVE-2 phase 3 clinical trial for VRDN-001 in patients with chronic Thyroid Eye Disease (TED), exceeding its target with 188 patients. Topline data for THRIVE-2 is expected by year-end 2024, while data for the THRIVE trial is expected in September 2024.
July 25, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viridian Therapeutics has completed enrollment for its THRIVE-2 phase 3 clinical trial for VRDN-001, exceeding its target with 188 patients. Topline data for THRIVE-2 is expected by year-end 2024, while data for the THRIVE trial is expected in September 2024.
The completion of enrollment and exceeding targets for the THRIVE-2 trial is a positive development for Viridian Therapeutics. It indicates strong patient demand and progress in their clinical trials, which could lead to positive topline data readouts in 2024. This news is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100